HM15211
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Hanmi · Phase 1 · Completed · Enrollment 41
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r |
| Cohort 4 | n/r | n/r | n/r | n/r |
| Cohort 5 | n/r | n/r | n/r | n/r |
Not shown
- Cohort 1: endpoint not reported
- Cohort 2: endpoint not reported
- Cohort 3: endpoint not reported
- Cohort 4: endpoint not reported
- Cohort 5: endpoint not reported